Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Historique:
received: 29 09 2020
revised: 16 12 2020
accepted: 16 12 2020
pubmed: 23 1 2021
medline: 2 2 2022
entrez: 22 1 2021
Statut: ppublish

Résumé

Recent innovations in the field of liver transplantation have led to a wealth of new treatment regimes, with potential impact on the onset of de novo malignancies (DNM). The aim of this multicenter cohort study was to provide contemporary figures for the cumulative incidences of solid and hematological DNM after liver transplantation. We designed a retrospective cohort study including patients undergoing LT between 2000 and 2015 in three Italian transplant centers. Cumulative incidence was calculated by Kaplan-Meyer analysis. The study included 789 LT patients with a median follow-up of 81 months (IQR: 38-124). The cumulative incidence of non-cutaneous DNM was 6.2% at 5-years, 11.6% at 10-years and 16.3% at 15-years. Post-Transplant Lymphoproliferative Disorders (PTLD) were demonstrated to have a cumulative incidence of 1.0% at 5-years, 1.6% at 10-years and 2.2% at 15-years. Solid Organ Tumors (SOT) demonstrated higher cumulative incidences - 5.3% at 5-years, 10.3% at 10-years and 14.4% at 15-years. The most frequently observed classifications of SOT were lung (rate 1.0% at 5-years, 2.5% at 10-years) and head & neck tumors (rate 1.3% at 5-years, 1.9% at 10-years). Lung tumors and head & neck tumors are the most frequently observed SOT after LT.

Sections du résumé

BACKGROUND
Recent innovations in the field of liver transplantation have led to a wealth of new treatment regimes, with potential impact on the onset of de novo malignancies (DNM). The aim of this multicenter cohort study was to provide contemporary figures for the cumulative incidences of solid and hematological DNM after liver transplantation.
METHODS
We designed a retrospective cohort study including patients undergoing LT between 2000 and 2015 in three Italian transplant centers. Cumulative incidence was calculated by Kaplan-Meyer analysis.
RESULTS
The study included 789 LT patients with a median follow-up of 81 months (IQR: 38-124). The cumulative incidence of non-cutaneous DNM was 6.2% at 5-years, 11.6% at 10-years and 16.3% at 15-years. Post-Transplant Lymphoproliferative Disorders (PTLD) were demonstrated to have a cumulative incidence of 1.0% at 5-years, 1.6% at 10-years and 2.2% at 15-years. Solid Organ Tumors (SOT) demonstrated higher cumulative incidences - 5.3% at 5-years, 10.3% at 10-years and 14.4% at 15-years. The most frequently observed classifications of SOT were lung (rate 1.0% at 5-years, 2.5% at 10-years) and head & neck tumors (rate 1.3% at 5-years, 1.9% at 10-years).
CONCLUSIONS
Lung tumors and head & neck tumors are the most frequently observed SOT after LT.

Identifiants

pubmed: 33482364
pii: S1665-2681(21)00008-9
doi: 10.1016/j.aohep.2021.100309
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

100309

Informations de copyright

Copyright © 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Cristina Lucidi (C)

Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Marco Biolato (M)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy.

Quirino Lai (Q)

Hepato-biliopancreatic and Liver Transplant Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy.

Barbara Lattanzi (B)

Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Ilaria Lenci (I)

Hepatology Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy.

Martina Milana (M)

Hepatology Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy.

Raffaella Lionetti (R)

Infectious and Liver Diseases, Lazzaro Spallanzani National Infectious Disease Institute, Rome, Italy.

Antonio Liguori (A)

Catholic University of the Sacred Heart, Rome, Italy.

Mario Angelico (M)

Hepatology Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy.

Giuseppe Tisone (G)

Surgery Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy.

Alfonso Wolfango Avolio (AW)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy.

Salvatore Agnes (S)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy.

Massimo Rossi (M)

Hepato-biliopancreatic and Liver Transplant Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy.

Antonio Grieco (A)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy.

Manuela Merli (M)

Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: manuela.merli@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH